InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: thefamilyman post# 315030

Sunday, 07/26/2020 4:36:36 PM

Sunday, July 26, 2020 4:36:36 PM

Post# of 403099
More old news but good news. Newbys might want to pay attention.

Also in April, Innovation disclosed it was in talks with health care provider networks and hospitals in the U.S. and Europe to “rapidly” advance Brilacidin testing into human trials, and announced a study published in the International Journal of Infectious Diseases supporting Brilacidin’s direct inhibition of SARS-CoV-2, based on testing on Vero cells. According to Innovation, the antiviral activity showed Brilacidin’s 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—against COVID-19 and associated complications. In other indications, the company said, Brilacidin has shown the ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines identified as key drivers in worsening prognoses of COVID-19 patients.



https://www.genengnews.com/covid-19-candidates/innovation-pharmaceuticals/


"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News